A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

NCT04802759 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

316

Enrollment

INDUSTRY

Sponsor class

Conditions

Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer

Interventions

DRUG: Giredestrant
DRUG: Abemaciclib
DRUG: Ipatasertib
DRUG: Inavolisib
DRUG: Ribociclib
DRUG: Everolimus
DRUG: Samuraciclib
DRUG: PH FDC SC
DRUG: Palbociclib
DRUG: Atezolizumab

Sponsor

Hoffmann-La Roche